Coherus Oncology (CHRS) Interest Expenses (2013 - 2026)

Coherus Oncology has disclosed Interest Expenses across 14 years of filings, most recently posting $2.2 million for Q1 2026.

• Interest Expenses for Q1 2026 came in at $2.2 million, up 1.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.0 million (down 17.48% YoY), and the FY2025 annual result was $9.0 million, down 16.14% from the prior year.
• Interest Expenses came in at $2.2 million for Q1 2026 at Coherus Oncology, down from $2.2 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $10.6 million in Q4 2023 to a low of $1.9 million in Q4 2024.
• The 5-year median for Interest Expenses is $4.1 million (2024), against an average of $5.7 million.
• Across the five-year window, Interest Expenses jumped 62.01% in 2022 and plunged 81.99% in 2024, its largest moves.
• Coherus Oncology's Interest Expenses stood at $9.4 million in 2022, then grew by 13.15% to $10.6 million in 2023, then slumped by 81.99% to $1.9 million in 2024, then advanced by 17.63% to $2.2 million in 2025, then dropped by 2.8% to $2.2 million in 2026.
• The last three Interest Expenses figures came in at $2.2 million (Q1 2026), $2.2 million (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.